SLC5A2 and heart failure: Animal studies suggest that CGRP has vascular-dependent and vascular-independent processes by which it could protect the vasculature and myocardium against cardiovascular dysfunction, particularly heart failure,18 to a similar extent as the SGLT2 inhibitors.